Pharmacotherapy in post-stroke rehabilitation

Lyukmanov R.Kh.; Rimkevichus A.A.; Gnedovskaya E.V.; Suponeva N.A.

doi:https://doi.org/10.17116/jnevro202212206140

Close metadata

Recommended articles:

Asthenia in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):5-10

Effectiveness of comprehensive rehabilitation of patients after a stroke in terms of changes in clinical and functional characteristics. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):11-16

Methods for determining the extent of ischemic changes in brain matter in the prognosis of clinical outcome after successful thromboextraction. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):17-27

Confirmation of the competitive validity of the Russian Aphasiological Test, a new standardized tool for the diagnosis of aphasia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):28-34

Cerebrolysin and the optimal timing of anticoagulation resumption in stroke: combined post hoc survival analysis of the CEREHETIS trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):77-93

Adjuvant pharmacological modulation with Cytoflavin in rehabilitation at stages 2—3 in patients with acute cerebral insufficiency and post-intensive care syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):78-85

The state of mental health of migrant workers and citizens of the Russian Federation: A comparative analysis as illustrated by the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):95-101

Factors of depression according to actigraphy in the fall season. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):27-32

Frailty in patients with atrial fibrillation: diagnosis, management, prevention and influence on prognosis. Russian Cardiology Bulletin. 2025;(1):5-12

Contemporary aspects of brain protection in aortic arch surgery. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):164-173

Abstract:

The article presents data on the conditions of use and efficacy of botulinum toxin preparations, oral muscle relaxants, selective serotonin reuptake inhibitors, acetylcholinesterase inhibitors and a glutamatergic transmission modulator in post-stroke neurorehabilitation, and provides recommendations for their rational and safe use. The clinical efficacy of Mexidol, which has a polymodal effect on a wide range of post-stroke disorders, especially in long-term sequential therapy, is discussed. A complex use of post-stroke rehabilitation methods with the determination of individual tactics based on the clinical picture of the patient and the defined rehabilitation goals is recommended. The inclusion of Mexidol in the complex therapy of patients with stroke consequences for tasks related to improving motor, affective and cognitive functions and self-care and quality of life looks promising. It is necessary to continue high-quality clinical studies to assess the pharmaceuticals efficacy in relation to post-stroke disorders.

Keywords:

stroke

hemiparesis

spasticity

depression

dementia

neurorehabilitation

pharmacotherapy

Authors:

Lyukmanov R.Kh.

Research Center of Neurology

SPIN RSCI: 2148-6716
Scopus AuthorID: 57188594033
ResearcherID: X-5954-2019
ORCID: 0000-0002-8671-5861

Rimkevichus A.A.

Research Center of Neurology

SPIN RSCI: 9502-3261
Scopus AuthorID: 57223433540
ORCID: 0000-0001-6967-2022

Gnedovskaya E.V.

Research Center of Neurology

Suponeva N.A.

Research Center of Neurology

SPIN RSCI: 3223-6006
Scopus AuthorID: 35773598900
ResearcherID: B-4686-2012
ORCID: 0000-0003-3956-6362

Received:

11.05.2022

Accepted:

16.05.2022

Close metadata

References:

Katan M, Luft A. Global Burden of Stroke. Semin Neurol. 2018;38(2):208-211. https://doi.org/10.1055/s-0038-1649503
Piradov MA, Maksimova MYu, Tanashian MM. Insul’t: sovremenny’e tehnologii diagnostiki i lecheniya. Rukovodstvo dlya vrachej. M.: MEDpressinform; 2018. (In Russ.).
Correction to: Guidelines for Adult Stroke Rehabilitation and Recovery: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2017;48(2):e78. https://doi.org/10.1161/STR.0000000000000120
Chervyakov AV, Poydasheva AG, Lyukmanov RH, et al. Effects of Navigated Repetitive Transcranial Magnetic Stimulation After Stroke. J Clin Neurophysiol. 2018;35(2):166-172. https://doi.org/10.1097/WNP.0000000000000456
Chernikova LA, Suponeva NA, Klochkov AS, et al. Robotic and Mechanotherapeutic Technology to Restore the Functions of the Upper Limbs: Prospects for Development (Review). Sovremennye Tehnologii v Medicine. 2016;8(4):222-230. https://doi.org/10.17691/stm2016.8.4.27
Soyuz Reabilitologov Rossii, Diagnostika i lechenie sindroma spastichnosti u vzrosly’h pacientov s ochagovy’mi porazheniyami central’noj nervnoj sistemy’ i ih posledstviyami v ramkah okazaniya stacionarnoj i ambulatorno-poliklinicheskoj medicinskoj pomoshhi, 2016: Moskva. (In Russ.).
Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818-1826.
Hulme A, MacLennan WJ, Ritchie RT, et al. Baclofen in the elderly stroke patient its side-effects and pharmacokinetics. Eur J Clin Pharmacol. 1985;29(4):467-469.
Jamous A, Kennedy P, Grey N. Psychological and emotional effects of the use of oral baclofen: a preliminary study. Paraplegia. 1994;32(5):349-353.
Goldstein E, Spasticity management: an overview. J Child Neurol. 2001;16(1):16-23.
Khatkova SE, Orlova OR, Botsina AYu, et al. basic principles of managing the patients with impaired tone after focal brain damage. Consilium Medicum. 2016;18(2.1):25-33. (In Russ.).
Gracies JM, Brashear A, Jech R, et al. Safety and efficacy of abobotulinumtoxin A for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. The Lancet. Neurology. 2015;14(10):992-1001.
Barnes M, Johnson G.R. UMN syndrome and spasticity. Cambridge University Press. 2008.
Rosales R, Efendy F, Teleg E, et al. Botulinum toxin as early intervention for spasticity after stroke or non-progressive brain lesion: A meta-analysis. J Neurol Sci. 2016;371:6-14.
Rimkevichus AA, Lyukmanov RKh, Shalimanova EV, et al. Pervy’j opy’t primeneniya botulinicheskogo toksina tipa A pri central’nom prozopareze. Farmateka. 2022;29(3):83-90. (In Russ.). https://doi.org/10.18565/pharmateca.2022.3.83-90
Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301(5634):805-809.
Lim CM, Kim SW, Park JY, et al. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res. 2009;87(4):1037-1045.
Glanzman DL. Postsynaptic regulation of the development and long-term plasticity of Aplysia sensorimotor synapses in cell culture. J Neurobiol. 1994;25(6):666-693.
Acler M, Robol E, Fiaschi A. A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke. J Neurol. 2009;256(7):1152-1158.
Elliott P, Wallis D. Serotonin and L-norepinephrine as mediators of altered excitability in neonatal rat motoneurons studied in vitro. Neurosci. 1992;47(3):533-544.
Gainotti G, Antonucci G, Marra C, Paolucci S. Relation between depression after stroke, antidepressant therapy, and functional recovery. J Neurol Neurosurg Psychiatry. 2001;71(2):258-261. https://doi.org/10.1136/jnnp.71.2.258
Chollet F, Tardy J, Albucher JF, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10(2):123-130. https://doi.org/10.1016/S1474-4422(10)70314-8
Vélez FG, Ferreira IS, Lucena PH, et al. Combining Fluoxetine and rTMS in Poststroke Motor Recovery: A Placebo-Controlled Double-Blind Randomized Phase 2 Clinical Trial. Neurorehabil Neural Repair. 2019;33(8):643-655. https://doi.org/10.1177/1545968319860483
Paolucci S, Antonucci G, Grasso MG, et al. Post-stroke depression, antidepressant treatment and rehabilitation results. A case-control study. Cerebrovasc Dis. 2001;12(3):264-271. https://doi.org/10.1159/000047714
Stuckart I, Siepmann T, Hartmann C, et al. Sertraline for Functional Recovery After Acute Ischemic Stroke: A Prospective Observational Study. Front Neurol. 2021;12:734170. https://doi.org/10.3389/fneur.2021.734170
Asadollahi M, Ramezani M, Khanmoradi Z, Karimialavijeh E. The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. Clin Rehabil. 2018;32(8):1069-1075. https://doi.org/10.1177/0269215518777791
Hatem SM, Saussez G, Della Faille M, et al. Rehabilitation of Motor Function after Stroke: A Multiple Systematic Review Focused on Techniques to Stimulate Upper Extremity Recovery. Front Hum Neurosci. 2016;10:442. https://doi.org/10.3389/fnhum.2016.00442
Zhou S, Liu S, Liu X, Zhuang W. Selective serotonin reuptake inhibitors for functional independence and depression prevention in early stage of post-stroke: A meta-analysis. Medicine (Baltimore). 2020;99(6):e19062. https://doi.org/10.1097/MD.0000000000019062
Legg LA, Rudberg AS, Hua X, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2021;11(11):CD009286. https://doi.org/10.1002/14651858.CD009286.pub4
Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: a systematic review of observational studies. Stroke. 2005;36(6):1330-1340. https://doi.org/10.1161/01.STR.0000165928.19135.35
Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery. Stroke. 2016;47(6):98-169.
Robinson RG, Jorge RE. Post-stroke depression: a review. Am J Psychiatry. 2016;173(3):221-231.
Medeiros GC, Roy D, Kontos N, Beach SR. Post-stroke depression: A 2020 updated review. Gen Hosp Psychiatry. 2020;66:70-80. https://doi.org/10.1016/j.genhosppsych.2020.06.011
Towfighi A, Ovbiagele B, El Husseini N, et al. American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Poststroke Depression: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2017;48(2):30-43. https://doi.org/10.1161/STR.0000000000000113
Li X, Zhang C. Comparative efficacy of nine antidepressants in treating Chinese patients with post-stroke depression: A network meta-analysis. J Affect Disord. 2020;266:540-548. https://doi.org/10.1016/j.jad.2020.02.005.
Hackett ML, Anderson CS, House A, Xia J. Interventions for treating depression after stroke. Cochrane Database Syst Rev. 2008:CD003437.
Allida S, Cox KL, Hsieh CF, et al. Pharmacological, psychological, and non-invasive brain stimulation interventions for treating depression after stroke. Cochrane Database Syst Rev. 2020;1(1):CD003437. https://doi.org/10.1002/14651858.CD003437
Lyukmanov RK, Rimkevichus AA, Shalimanova EV, et al. Motor neurorehabilitation in patients with epileptic seizures: limitations of methods with proven efficacy in stroke. Epilepsy and Paroxysmal Conditions. 2021;13(1):51-64. (In Russ.). https://doi.org/10.17749/2077-8333/epi.par.con.2021.043
Woranush W, Moskopp ML, Sedghi A, et al. Preventive Approaches for Post-Stroke Depression: Where Do We Stand? A Systematic Review. Neuropsychiatr Dis Treat. 2021;17:3359-3377. https://doi.org/10.2147/NDT.S337865
Viana R, Teasell R, Mehta S. Cognitive-behavioral therapy for managing depressive and anxiety symptoms after stroke: systematic review and meta-analysis. Top Stroke Rehabil. 2022;23:1-16. https://doi.org/10.1080/10749357.2022.2049505
Kampling H, Baumeister H, Bengel J, Mittag O. Prevention of depression in adults with long-term physical conditions. Cochrane Database Syst Rev. 2021;3(3):CD011246. https://doi.org/10.1002/14651858.CD011246.pub2
Rost NS, Brodtmann A, Pase MP, et al. Post-Stroke Cognitive Impairment and Dementia. Circ Res. 2022;130(8):1252-1271. https://doi.org/10.1161/CIRCRESAHA.122.319951
Jokinen H, Melkas S, Ylikoski R, et al. Post-stroke cognitive impairment is common even after successful clinical recovery. Eur J Neurol. 2015;22(9):1288-1294. https://doi.org/10.1111/ene.12743
Kalaria RN, Akinyemi R, Ihara M. Stroke injury, cognitive impairment and vascular dementia. Biochim Biophys Acta. 2016;1862(5):915-925. https://doi.org/10.1016/j.bbadis.2016.01.015
Lanctôt KL, Lindsay MP, Smith EE, et al. Management of Mood, Cognition and Fatigue Following Stroke Best Practice Writing Group, the Heart & Stroke Canadian Stroke Best Practices and Quality Advisory Committee; in collaboration with the Canadian Stroke Consortium. Canadian stroke best practice recommendations: mood, cognition and fatigue following stroke, 6th edition update 2019. Int J Stroke. 2020;15:668-688. https://doi.org/10.1177/1747493019847334
O’Donoghue M, Leahy S, Boland P, et al. Rehabilitation of cognitive deficits poststroke: systematic review and meta-analysis of randomized controlled trials. Stroke. [published online February 3, 2022]. https://doi.org/10.1161/STROKEAHA.121.034218
Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6:782-792. https://doi.org/10.1016/S1474-4422(07)70195-3
Dichgans M, Markus HS, Salloway S, et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol. 2008;7:310-318. https://doi.org/10.1016/S1474-4422(08)70046-2
McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019;3:CD003154. https://doi.org/10.1002/14651858.CD003154.pub6
Zhang X, Shu B, Zhang D, et al. The Efficacy and Safety of Pharmacological Treatments for Post-stroke Aphasia. CNS Neurol Disord Drug Targets. 2018;17(7):509-521. https://doi.org/10.2174/1871527317666180706143051
Narasimhalu K, Effendy S, Sim CH, et al. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Acta Neurol Scand. 2010;121:217-224. https://doi.org/10.1111/j.1600-0404.2009.01263.x
Battle CE, Abdul-Rahim AH, Shenkin SD, et al. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database Syst Rev. 2021;2:CD013306. https://doi.org/10.1002/14651858.CD013306.pub2
Voronina TA. Mexidol: main neuropsychotropic effects and mechanisms of action. Psihofarmakologiya, Biologiya, Narkologiya. 2001;1(1):2-12. (In Russ.).
Gromova OA, Torshin IYu, Sardaryan IS, et al. Sravnitel’ny’ĭ hemoreaktomny’ĭ analiz meksidola. Farmakokinetika i Farmakodinamika. 2016;4:19-30. (In Russ.).
Skvortsova VI, Stakhovskaya LV, Nartsissov YaR, et al. Randomized double blind placebo-controlled study of Mexidol efficacy and safety in the treatment of ischemic stroke in the acute period. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2006;18(2):47-54. (In Russ.).
Zhang L, Wang H. Targeting the NF-E2-Related Factor 2 Pathway: a Novel Strategy for Traumatic Brain Injury. Molecular Neurobiology. 2018;55(2):1773-1785. https://doi.org/10.1007/s12035-017-0456-z
Shchul’kin AV. Effect of mexidol on the development of the phenomenon of the neuronal excitotoxicity in vitro. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2012;112(2):35-39. (In Russ.).
Shchul’kin AV. Sovremenny’e predstavleniya ob antigipoksicheskom i antioksidantnom e’ffektax meksidola. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2018;12(2):87-93. (In Russ.).
Yakusheva EN, Mylnikov PY, Chernykh IV, Shchulkin AV. An effect of mexidol on the expression of the transcription factor Nrf2 in the rat cerebral cortex in ischemia. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2018;118(5):64-68. (In Russ.). https://doi.org/10.17116/jnevro20181185164
Voronina TA. Mexidol: the spectrum of pharmacological effects. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2012;112(12):86-90. (In Russ.).
Voronkov AV, Pozdnyakov DI, Khuri EI, Rybalko AE. Comparison of mexidol antioxidant activity of various genesis brain damage in experiment. Sovremenny’e Problemy’ Nauki i Obrazovaniya. 2016;6:23-29. (In Russ.).
Luk’yanova LD. Signal’ny’e mexanizmy’ gipoksii. Monografiya. M.: RAS; 2019;214. (In Russ.).
Odinak MM, Ianishevskiĭ SN, Tsygan NV, et al. The use of succinates for the correction of metabolic disorders in the penumbra in patients with stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2013;113(12-2):55-60. (In Russ.).
Zhulev NM, Pustozerov VG, Saikova LA. Primenenie meksidola v lechenii bol’ny’h nasledstvenny’mi nervno-my’shechny’mi zabolevaniyami. Bulleten’’ E’ksperimental’noi Biologii I Mediciny’. M. 2006;22-27. (In Russ.).
Kirova YI, Shakova FM, Germanova EL, et al. The effect of Mexidol on cerebral mitochondriogenesis at a young age and during aging. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2020;120(1):62-69. (In Russ.). https://doi.org/10.17116/jnevro202012001162
Koval’chuk VV, Skoromecz AA. Vozmozhnosti meksidola pri vosstanovlenii pacientov posle insul’ta. Medlain-E’kspress. 2009;203:4-6. (In Russ.).
Koval’chuk VV. Vliyanie Meksidola na nevrologicheskii deficit, social’no-by’tovuyu adaptaciyu i sindromy’ neglekta i «ottalkivaniya» u pacientov posle insul’ta. Zhurnal nevrologii i psixiatrii im. S.S. Korsakova. 2011;111:12(2):52-57. (In Russ.).
Koval’chuk VV, Barancevich ER, Galkin AS. Mul’tidisciplinarny’j princip vedeniya pacientov posle insul’ta. Kriterii e’ffektivnosti i faktory’ uspeha fizicheskoj, nejropsihologicheskoj i medikamentoznoj reabilitacii. E’ffektivnaya Farmakoterapiya. 2020;16(31):10-22. (In Russ.). https://doi.org/10.33978/2307-3586-2020-16-31-10-22
Zhuravleva MV, Shchukin IA, Fidler MS, et al. Efficacy and safety of ethylmethylhydroxypyridine succinate in patients with ischemic stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(12-2):60-66. (In Russ.). https://doi.org/10.17116/jnevro202012012260
Kuzneczova SM, Kuzneczov VV, Yurchenko FV. Meksidol v reabilitacii bol’ny’x pozhilogo vozrasta, perenesshix insul’t. Farmateka. 2009;15:105-108. (In Russ.).
Kuznetsov VV, Iurchenko FV. Effects of mexidol on the functional state of the central nervous system in post-stroke patients. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(6):18-20. (In Russ.).
Kashin AV. E’ffektivnost’ i bezopasnost’ meksidola v lechenii kognitivnoi disfunkcii u pacientov, perenesshix ishemicheskii insul’t. Bulleten’ e’ksperimental’noi Nevrologii i Mediciny. 2012;5:34-36. (In Russ.).
Voronina TA. Geroprotective effects of ethylmethylhydroxypyridine succinate in an experimental study. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(4):81-87. (In Russ.). https://doi.org/10.17116/jnevro202012004181
Stakhovskaya LV, Shamalov NA, Khasanova DR, et al. Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and recovery stages of hemispheric ischemic stroke (EPICA). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(3-2):55-65. (In Russ.). https://doi.org/10.17116/jnevro20171173255-65
Fedin AI, Zakharov VV, Tanashyan MM, et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(11):7-16. (In Russ.). https://doi.org/10.17116/jnevro20211211117
Stakhovskaya LV, Mkhitaryan EA, Tkacheva ON, et al. Efficacy and safety of mexidol across age groups in the acute and early recovery stages of hemispheric ischemic stroke (results of additional sub-analysis of a randomized double blind multicenter placebo-controlled study EPICA). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020;120(8-2):49-57. (In Russ.). https://doi.org/10.17116/jnevro202012008249
Ishemicheskij insul’t i tranzitornaya ishemicheskaya ataka u vzrosly’h. Klinicheskie rekomendacii 2021 g. (In Russ.). https://cr.minzdrav.gov.ru/schema/171_2